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Background: The expansion of adipose tissue is linked to the development of its vasculature, which appears to
have the potential to regulate the onset of obesity. However, at present, there are no studies highlighting the
relationship between human adipose tissue angiogenesis and obesity-associated insulin resistance (IR).
Results: Our aim was to analyze and compare angiogenic factor expression levels in both subcutaneous (SC) and
omentum (OM) adipose tissues from morbidly obese patients (n = 26) with low (OB/L-IR) (healthy obese) and high
(OB/H-IR) degrees of IR, and lean controls (n = 17). Another objective was to examine angiogenic factor
correlations with obesity and IR.
Here we found that VEGF-A was the isoform with higher expression in both OM and SC adipose tissues, and was
up-regulated 3-fold, together with MMP9 in OB/L-IR as compared to leans. This up-regulation decreased by 23% in
OB/-H-IR compared to OB/L-IR. On the contrary, VEGF-B, VEGF-C and VEGF-D, together with MMP15 was down-
regulated in both OB/H-IR and OB/L-IR compared to lean patients. Moreover, MMP9 correlated positively and VEGF-
C, VEGF-D and MMP15 correlated negatively with HOMA-IR, in both SC and OM.
Conclusion: We hereby propose that the alteration in MMP15, VEGF-B, VEGF-C and VEGF-D gene expression may be
caused by one of the relevant adipose tissue processes related to the development of IR, and the up-regulation of
VEGF-A in adipose tissue could have a relationship with the prevention of this pathology.
Keywords: Vascular Endothelial Growth Factor and Metalloproteinase, Obesity, Insulin Resistance, Omentum Adi-
pose Tissue, Subcutaneous Adipose Tissue
Background
The prevalence of obesity has increased dramatically in
the last decades and is now considered a major health
problem. In fact, the current epidemic of obesity has
been suggested as the leading cause for the decreased
life expectancy forecast for the next generation. Obesity
is very often accompanied by other diseases, the most
common being type 2 diabetes mellitus (T2DM) and
cardiovascular complications [1-3].
T2DM and obesity both involve genetic and environ-
mental factors. However, progression to overt diabetes
in patients with obesity is not clearly predicted. Like-
wise, while some obese individuals progress to T2DM,
others only have mild metabolic abnormalities suggest-
i n gt h a tt h ea b s o l u t ea m o u n to ff a ts t o r e dm a yn o tb e
the most important factor in determining the relation-
ship between obesity and T2DM [4-7].
Adipose tissue expandability in response to positive
energy balance has traditionally been considered an adap-
tive passive process. However, recent evidence suggests
that the expandability of adipose tissue is not an unlim-
ited process. In fact, adipose tissue expandability may be
an important factor determining the appearance of
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have shown the prevalence of a negative IR status and no
complications in patients with severe morbid obesity
(Metabolically healthy, but obese individuals) [10-12].
Adipose tissue expansion is well known to be linked to
the development of its vasculature [13]. Furthermore, it
has been described that obesity is associated with extensive
modifications in adipose tissue involving adipogenesis,
angiogenesis and proteolysis [14]. However, until now, no
studies have established the relationship between adipose
tissue angiogenic capacity, obesity and IR.
It is generally well known that the vascular endothelial
growth factor (VEGF) system accounts for most of the
angiogenic activity in adipose tissue [15]. VEGF-A (17-
23 kDa) is a major angiogenic factor that stimulates pro-
liferation and migration of ECs [16]. VEGF-B (21 kDa) is
43% identical to VEGF-A; it also promotes angiogenesis
and is implicated in extracellular matrix (ECM) degrada-
tion via the regulation of plasminogen activation [17].
VEGF-C displays a 30% homology with VEGF-A,a n d
plays an important role in both angiogenesis and lym-
phangiogenesis [18,19]. VEGF-D is 48% identical to
VEGF-C and also promotes the growth of lymphatic
vessels [20]. Matrix metalloproteinases (MMPs) are
essential for proper ECM remodeling, a process that
takes place during obesity-mediated adipose tissue for-
mation. The development of obesity is associated with
coordinated cellular processes, including adipocyte
hypertrophy followed by recruitment of adipocyte pre-
cursors, and new fat cell differentiation [21,22]. These
processes are also accompanied by neovascularization,
essential for the generation and proper function of adipose
tissue [23]. It is generally accepted that such multiple
events include dynamic changes of cell-matrix interactions
and extensive ECM remodeling, and that modifications in
proteolytic activities within the adipose microenvironment
might occur during the development of the fat depot.
Among enzymes implicated in the degradation of matrix
molecules and in the generation of bioactive factors,
the matrix metalloproteinase family is considered to be
primarily responsible for these processes [24]. These sub-
groups are collagenases, gelatinases, stromelysins, mem-
brane-type MMPs (MT-MMPs), and other MMPs [25,26].
MMPs participate in many physiological and pathological
processes such as embryonic development, angiogenesis,
wound repair, reproductive cycling, and metastasis [24,25].
Also, they can mediate the release and/or activation of
sequestered growth factors, including VEGFs, and the clea-
vage of cell surface adhesion receptors [25].
On the basis of all these antecedents our aim was to
analyze angiogenic factor and metalloproteinases expres-
sion levels in adipose tissue from control and obese sub-
jects with or without IR, to study the relationship between
adipose tissue-angiogenic factors/metalloproteinase, obe-
sity and IR.
Results
Anthropometric and biochemical characteristics of the
patients
The anthropometric and biochemical parameters from
controls and obese subjects (with low and with high insu-
lin resistance) are depicted in Table 1. The severely obese
patient group had a significantly higher body mass index
(BMI) and waist circumference (WC) (57.27 ± 2.07 kg/m2
and 144.4 ± 7.14) (p < 0.05 and p < 0.01 respectively) with
respect to lean subjects (Controls). No anthropometric dif-
ferences were observed between the two groups of obese
subjects with low and high degrees of insulin resistance.
Table 1 also illustrates the biochemical abnormalities asso-
ciated to obesity and IR, showing low levels of HDL cho-
lesterol in morbidly obese patients as compared to lean
subjects. Adiponectin, a protein hormone produced and
secreted by adipocytes and known to regulate the metabo-
lism of lipids and glucose and related to angiogenesis in
adipose tissue showed significantly low levels in obese
patients (p < 0.01). There were no differences in the
homeostasis model assessment (HOMA) indices between
healthy OB/L-IR and controls, and both groups in turn
displayed significant differences in this index respect to
the OB/H-IR group.
Angiogenesis related gene expression profiles in OM and
SC adipose tissues from leans, OB/H-IR and OB/L-IR
subjects
We performed mRNA expression analysis in a set of genes
involved in the regulation of angiogenesis in OM and SC
samples from lean and obese subjects both with low and
high degrees of IR. These genes are basically VEGF iso-
forms and proteolytic MMPs. Figure 1A shows that
VEGF-A gene expression was significantly enhanced in
OM from OB/L-IR (by about 3 fold) as compared to lean
subjects. VEGF-A gene expression up-regulation was sig-
nificantly reduced by about 23% in OB/H-IR subjects as
c o m p a r e dt oO B / L - I R .I nS C ,VEGF-A levels were lower
than those observed in OM, however the up-regulation of
this angiogenic form was also observed in both OB/L-IR
and OB/H-IR subjects compared to leans. These data indi-
cate the high up-regulation of VEGF-A isoform in both SC
and OM adipose tissues from healthy morbidly obese sub-
jects and this up-regulation was diminished in morbidly
obese subjects with IR.
However, VEGF-B gene expression was significantly
down-regulated in both OM and SC from OB/H-IR and
OB/L-IR subjects compared to leans, and no significant
differences were observed between OB/H-IR and OB/L-
IR subjects. Both VEGF- C and VEGF-D gene expressions
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OM and SC from OB/H-IR and OB/L-IR subjects com-
pared to leans. Moreover, VEGF- B, VEGF-C and VEGF-
D expression levels were much lower in both OM and
SC as compared to VEGF-A isoforms.
VEGF isoform protein expressions were also analyzed in
both OM and SC from leans and OB/H-IR and OB/L-IR
subjects. Figure 1B shows evidence for the presence of
protein synthesis of the four VEGF isoforms in both OM
and SC in all the subjects. These protein analyses con-
firmed the results obtained by real time PCR, showing that
VEGF-A is the isoform more abundant in both OM and
SC as compared to the other isoforms, and that this iso-
form is especially enhanced in obese subjects compared to
leans. In addition, we observed that VEGF-B, VEGF-C and
VEGF-D protein expression was decreased in obese sub-
jects compared to leans, especially in those with high
degrees of insulin resistance (Figure 1B).
MMP9 gene expression levels were significantly
enhanced especially in SC from both OB/H-IR and OB/L-
IR subjects compared with leans (Figure 1C). In fact, in
OM, MMP9 expression was about 25% higher in OB/L-IR
subjects than in leans, and about 50% higher in OB/H-IR
compared to leans. In SC, the differences in MMP9 gene
expression were even higher than in OM. In fact, SC
MMP9 gene expression was 3-fold higher in OB/L-IR sub-
jects than in leans, and about 6-fold higher in OB/H-IR
subjects than in leans. When comparing SC MMP9 gene
expression in the two obese groups, its expression was 80%
higher in OB/H-IR subjects than in OB/L-IR (Figure 1C).
Opposite, MMP15 expression showed significant down-
regulation in both OM and SC from both OB/H-IR and
OB/L-IR subjects compared to leans (Figure 1C). In fact,
OM MMP15 gene expression was lower by approximately
50% in OB/H-IR and OB/L-IR subjects compared to leans,
and this difference was statistically significant. Also, SC
MMP15 gene expression levels were approximately 33%
lower in OB/L-IR subjects than in leans and by about 40%
lower in OB/H-IR compared to leans.
Correlation analysis with HOMA and IR
Correlation analysis of the different genes studied with
HOMA, the parameter determining the subjects’ insulin
resistance indicated that VEGF-C and VEGF-D from both
SC and OM correlated negatively with the HOMA index
(Figure 2A-D). Nevertheless, when we examined the corre-
lation between VEGF-A and HOMA, no correlations was
observed in both OM and SC. Moreover, we observed that
MMP9 metalloproteinase correlated positively with
HOMA (Figure 2E and 2F). However, MMP15 showed a
clear negative correlation with HOMA in both SC and
OM tissues (Figure 2G and 2H). On the other hand, when
we analyzed the correlations between VEGF isoforms and
the MMPs we noted that MMP15 correlates positively
with VEGF-C (r = 0.53, p <0 . 0 2 ) .MMP9 showed a signifi-
cant negative correlation with VEGF-C (r = -0.48, p <
0.05), and positive correlation with VEGF-A (r = 0.33, p <
0.05). Moreover, analyzing the potential correlations
between VEGF isoforms, we observed a positive and sig-
nificant correlation between VEGF-C and VEGF-B (r =
0.60, p < 0.05) and between VEGF-C and VEGF-D (r =
0.77, p < 0.001). However, no significant correlation was
observed between VEGF-A and others VEGF isoforms. On
the other hand, when we analyzed the correlations
between these angiogenic parameters and HOMA index
in obese group, we observed that the results showed the
same trends as in above statistical analysis, although some
correlations did not show significant differences (Table 2)
Discussion
Modulation of angiogenesis can potentially impair the
development of obesity-associated co-morbidities. How-
ever, little is known of the relationship between angiogenic
components and insulin resistance in human adipose
tissues.
The fact that some morbidly obese subjects having
VEGF-A overexpressed in their adipose tissue did not
develop IR leads us to believe that the enhancement of
VEGF-A, which is known be responsible for most of
Table 1 Clinicopathological characteristics and biomarker parameters
Control (n = 17) OB/non IR (n = 12) OB/H-IR (n = 14) p
Age (years) 44.46 ± 2.2
a 43.64 ± 3.22
a 37.50 ± 2.90
a -
BMI 23.04 ± 0.32
a 57.28 ± 2.40
b 57.26 ± 1.75
b < 0.05
Triglycerides (mM) 1.14 ± 0.15 1.19 ± 0.15 1.13 ± 0.36 -
HOMAindex 1.23 ± 0.14
a 3.31 ± 0.24
a 13.79 ± 1.28
b < 0.01
Adiponectin (μg/mL) 12.48 ± 1.26
a 10.83 ± 1.54
b 9.07 ± 1.52
b < 0.01
Cholesterol (mM) 4.91 ± 0.29
a 5.38 ± 0.45
a 5.02 ± 0.19
a -
Cholesterol HDL (mM) 1.42 ± 0.14a 0.93 ± 0.20
b 1.04 ± 0.12
b 0.05
Waist circumference 82.03 ± 1.95 142.8 ± 6.88 146.0 ± 7.41 < 0.01
Data are mean ± SEM. BMI: body mass index, HOMA index: homeostasis model assessment index. Comparison of high degree insulin resistant (OB/H-IR) and low
degree insulin resistant (OB/L-IR) obese subjects versus controls was assessed by ANOVA test. Groups with different letters showed significant differences.
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Page 3 of 8Figure 1 VEGF isoforms, MMP9, MMP15 mRNA and protein expression in omentum and subcutaneous AT from subjects.( A )VEGF
isoforms [VEGF-A, VEGF-B, VEGF-C and VEGF-D] mRNA expression analysis was performed on human omentum (OM) and subcutaneous (SC)
adipose tissues from three subject groups (lean, OB/H-IR and OB/L-IR subjects). mRNAs were normalized to cyclophilin levels. Results were
obtained from triplicate and expressed as the mean ± SEM (n = 17 for controls, n = 12 for OB/L-IR and n = 14 for OB/H-IR). Bars with different
letters have a significant difference, p < 0.05. (B) Immunoblotting analysis of VEGF isoforms. The resulted blot of each isoform was compared to
Actin-b constitutive protein. Density analyze was done normalizing the samples to b-actin using NIH’s Image-J software program. The blot is
representative of three independent experiments with different samples, * p < 0.05. (C) Metalloproteinase (MMP9 and MMP15) mRNA expression
analysis was performed on human omentum (OM) and subcutaneous (SC) adipose tissues from three groups of subjects (leans, OB/H-IR and OB/
L-IR). mRNAs were normalized to cyclophilin levels. Bars with different letters have a significant difference (p < 0.05); differences are compared to
the control and between the two groups of obese.
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Page 4 of 8adipose tissue’s angiogenic capacity [26], could probably
be in response to the impaired lymphangiogenic capa-
city, which was reflected by VEGF-B, VEGF-C and
VEGF-D reduction. These mechanisms may somehow
have some relationship in preventing IR. In line with
our findings, it has been recently described that during
differentiation of 3 T3-F442A preadipocytes, VEGF-B
and VEGF-C mRNA levels are less modulated, whereas
that of VEGF-A are up-regulated [27]. Moreover, other
data show that in patients with abdominal obesity, sti-
mulation of SAT angiogenesis associated to insulin
resistance promotes SAT hyperplasia, thus enhancing
the storage capability of adipose tissue [28]. Our sugges-
tions may appear speculative, but we consider that the
significant negative correlation of VEGF-C and VEGF-D
with the HOMA index points to the possible relation-
ship between down regulation of these two isoforms and
insulin resistance development in morbidly obese sub-
jects. Our hypothesis is that down-regulation of these
angiogenic factors could be related to an alteration in
the insulin sensitivity signaling pathway, as it is well
known that insulin sensitivity signaling pathways involve
a variety of genes including VEGF, GLUT1 and hypoxia-
inducible factor HIF-1a/ARNT [29].
MMPs are proteolytic enzymes that play an essential
role in extracellular matrix remodeling and VEGF regula-
tion. MMPs are involved in two important events of this
process and control proteolysis and adipogenesis during
obesity-mediated fat mass development [30,31]. Several
previous studies have suggested a role for MMPs in adi-
pose tissue remodeling. Other studies have reported
altered levels of MMPs in disorders related to insulin
resistance [32]. Here, the up-regulation of gene expres-
sion of MMP9 and its positive correlation with the
HOMA index point to the potential relationship between
this metalloproteinase and insulin resistance develop-
ment in morbidly obese subjects. In accordance with our
suggestions, recent studies showed that MMP-9 expres-
sion in adipose tissue is increased with obesity and insu-
lin resistance and is increased in adipocytes, and this
increase in MMP-9 was related to the regulation of med-
iators of insulin signaling pathways such as PKCa and
PPARg [33]. Other researchers have provided the first
Figure 2 Correlative analysis of VEGF isoforms and MMPs with the HOMA index.C o r r e l a t i o no fVEGF-C and VEGF-D isoforms, MMP15 and
MMP9 mRNA expression with the HOMA index from both omentum (OM) and subcutaneous (SC) adipose tissues was determined by Pearson’s
correlation coefficient test (r).
Table 2 Correlations between VEGF isoforms and MMPs
gene expression with HOMA-IR in adipose tissue from
obese subjects
Rs p
VEGF-C-V/HOMA IR -0.404 0.054
VEGF-C-S/HOMA IR -0.412* 0.036
VEGF-D-V/HOMA IR -0.403* 0.021
MMP9-V/HOMA IR 0.439* 0.041
MMP9-S/HOMA IR 0.417 0.052
MMP15-S/HOMA IR -0.357 0.0652
Correlations were determined by Pearson’s correlation coefficient test *p < 0.05.
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that this secretion is modulated during adipocyte differ-
entiation [34]. Recent studies have also shown that
MMP9 expression was elevated in preadipocytes and the
stroma vascular fraction of obese subjects compared with
those of non-obese subjects [35].
We can say that we are the first to evaluate MMP-15
in adipose tissue and to propose the potential relation-
ship between it, obesity and insulin resistance. Down
regulation of gene expression MMP-15 and its signifi-
cant negative correlation with the HOMA index point
to the existence of a potential relationship between this
metalloproteinase, VEGF-C, VEGF-D and insulin resis-
tance in morbidly obese subjects.
Conclusions
In summary, our study highlights a group composed by the
angiogenic factor VEGF-A and a relevant regulator of ECM
degradation, MMP9, which in our opinion, could be acting
together in adipose tissue as a compensatory mechanism
that replaces the alteration in VEGF-B, VEGF-C, VEGF-D
and MMP15. These data add another fact related to the
metabolic derangements of obesity, including IR to the dis-
turbance of one of the functionalities of adipose tissue con-
trolled by VEGF and metalloproteinase angiogenic factors
factors.
Finally, we believe that a better understanding of the
regulation of the expression of these angiogenic compo-
nents in adipose tissue will thus be instrumental in the
development of specific therapeutic targeting approaches.
Methods
Patients and adipose tissue collection
The study was performed in morbidly obese patients
(n = 26) undergoing bariatric surgery at the Hospital
Clínico Virgen de la Victoria. Exclusion criteria were:
T2DM treated with insulin, cardiovascular disease in the
6 months prior to inclusion in the study, evidence of
acute or chronic inflammatory disease, infectious disease
or the patient’s decision not to participate in the study.
Control subjects (n = 17) were patients who underwent
laparoscopic surgery for hiatus hernia or cholelithiasis,
who were not obese, with a similar age to the morbidly
obese group, and with the same selection criteria.
The study groups were organized by:
- Morbidly obese: High insulin resistance (HOMA IR
>9 )s h o w ni nt h et e x ta s( O B / H - I R ) .L o wi n s u l i n
resistance (HOMA IR < 4) shown in the text as (OB/
L-IR). The cut-off was set at average plus two stan-
dard deviations of the values of a healthy control
population.
- Controls: BMI 18.5-24.9 without insulin resistance
All participants gave their informed consent, and the
study was reviewed and approved by the ethics and
research committee of the Vírgen de la Victoria Clinical
University Hospital (Malaga, Spain).
Both SC and OM adipose tissues were obtained at the
beginning of the surgical procedure and were stored
immediately at -80°C.
RNA extraction
Total RNA was isolated from adipose tissue using the
Trizol RNA isolation method (Invitrogen, Carlsbad, CA)
and purified with the RNeasy Lipid kit (QIAGEN -Ref.
74804-, Valencia, CA).
Real-time PCR
Amplifications were performed using a MicroAmp
®
Optical 96-well reaction plate (PE Applied Biosystems)
on an ABI 7500 Real-Time PCR System (Applied Bio-
systems). RT qPCR reactions were carried out for all
genes using specific TaqMan
® Gene Expression Assays.
During PCR, the Ct values for each amplified product
were determined using a threshold value of 0.1. The
specific signals were normalized by constitutively




® gene expression assay probes
VEGF-A: Ref. Hs00173626_m1. Sequence:
NM_001025366.2
VEGF-B: Ref. Hs00957984_m1. Sequence:
NM_003377.3
VEGF-C: Ref. Hs00153458_m1. Sequence:
NM_005429.2
VEGF-D: Ref. Hs01128659_m1. Sequence:
NM_004469.4
MMP9: Ref. Hs00234579_m1. Sequence:
NM_004994.2
MMP15: Ref. Hs00233997_m1. Sequence:
NM_002428.2
Western blot analysis
Total proteins from adipose tissues were extracted by
NE-PER Nuclear and Cytoplasmatic Extraction Reagents
protocol (Pierce -Ref.78833-). Protein extracts (30 μg)
were separated by SDS-PAGE, blotted onto a PVDF
membrane and then incubated with specific antibodies
(VEGF (A-20): sc-152; VEGF-B (J-14I): sc-80442; VEGF-C
(H-48): sc-25783; VEGF-D (X142): sc-80447; Santa Cruz
Biotechnology, INC. Monoclonal Anti-B-Actin: A5316;
Sigma Aldrich). Protein signals were detected by electro-
chemiluminescence detection Quantity One
® software
(Bio-Rad Laboratories).
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SPSS Inc. software (Version 15.0) was used for all statisti-
cal analyses. Comparisons between the normalized mRNA
levels of different genes and the biochemical characteris-
tics of the groups used in this study were made by
ANOVA test and the statistical differences between the
groups were made by Duncan’s test. The correlation ana-
lysis of mRNA quantitative expression of each of the
genes was performed with Pearson’s coefficient Test (r).
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